GRFS:NASDAQ
Grifols SA - ADR ADR Class B
$7.24
arrow_upward
+0.91%(+0.065) 1D
Oct 14, 3:16:54 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRFS...
Open
$7.29
High
$7.40
Low
$7.22
Mkt. cap
6.62B
Avg. vol.
547.40K
Volume
463.03K
Dividend
1.30%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
9.72
52-wk high
$9.90
52-wk low
$6.96
EPS
$0.74
Beta
0.70
Shares outstanding
261.42M
No. of employees
25K
Open
$7.29
High
$7.40
Low
$7.22
Mkt. cap
6.62B
Avg. vol.
547.40K
Volume
463.03K
Dividend
1.30%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
9.72
52-wk high
$9.90
52-wk low
$6.96
EPS
$0.74
Beta
0.70
Shares outstanding
261.42M
No. of employees
25K
News stories
From web sources and news partners
MarketBeat
·
7 hours ago
Grifols, S.A. (NASDAQ:GRFS) Shares Shorted: Short Interest Up 105.0% in September
ad-hoc-news.de
·
1 day ago
Wall Street Zen downgrades Grifols stock from Buy to Hold
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA - ADR ADR Class B